Summary:
A study to evaluate an already FDA approved medication for migraine treatment, and prevention. This study is being conducted to further evaluate the safety, efficacy and tolerability of every other day and daily dosing of Rimegepant (Nurtec ODT) in Episodic Migraine. This study requires about 5-13 in office visits, over a period of 36 weeks.
Qualified Participants Must:
• Must be 18 years or older
•
Have a diagnosis of migraine for at least 6 months
Qualified Participants May Receive:
Up to $975 if all study visits are completed